Age as an Independent Factor in the Permanent Chemotherapy-Induced Amenorrhea Incidence in Breast Cancer Patients at Dr. Moewardi Hospital, Surakarta, Indonesia

Mudib Mudib1, Kristanto Yuli Yarso2*, Henky Agung Nugroho2

1Department of Surgery, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia; 2Department of Surgery, Division of Oncology, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia

Abstract

BACKGROUND: Chemotherapy-induced amenorrhea (CIA) is one common side effect of chemotherapy in breast cancer patients. Some who have CIA may experience menstruation return while others experience permanent CIA.

AIM: This study aims to examine the factors that contribute to the incidence of persistent CIA in breast cancer patients.

METHODS: The population of this retrospective study was new breast cancer patients with premenopausal status when they started receiving chemotherapy at Dr. Moewardi Hospital, Surakarta, Indonesia, from January 2019 to July 2021. To determine the relationship, the Chi-square/Fisher’s exact test was performed. Risk factor analysis on the incidence of permanent CIA was carried out using a bivariate logistic regression test followed by multivariate analysis.

RESULTS: A number of 105 premenopausal breast cancer patients who received chemotherapy were found. Of these patients, 97 (93.38%) patients experienced CIA and 8 patients (6.62%) continued to menstruate. Of all the patients having CIA, 49 patients (46.67%) menstruated again while the other 48 (45.71%) had persistent CIA. Age factor has a significant relationship with the incidence of permanent CIA (p < 0.001), where patients aged >45 years tend to have permanent CIA incidence with a proportion of 42 patients (87.5%) (p < 0.05). The multivariate analysis showed that age >45 years (OR = 75.117; 95% CI = 12.671–445.311; p < 0.001) was the most dominant risk factor associated with the incidence of permanent CIA, while other variables as risk factors for permanent CIA based on multivariate analysis were Stage III (R = 6.677; 95% CI = 1.370–32,545; p = 0.019) compared to Stages I and II, and body mass index (BMI) in the normal category (OR = 5.485; 95% CI = 1.083–27.786; p = 0.040) compared to excess BMI. The other variables were not found to be associated with the incidence of permanent CIA.

CONCLUSION: Age is a major factor associated with persistent CIA incidence. Other factors related to this study are staging and BMI.

Introduction

Breast cancer is the most common cancer in women worldwide [1]. It has a high incidence rate in all countries, developing and least developed countries [2]. In developing countries, breast cancer cases account for more than half of new cancer cases and a quarter of all cancers [3]. One of the main concerns today is the trend of breast cancer in young women. GLOBOCAN 2018 reported that the number of breast cancer women younger than 45 years is 13.4/100,000 people/year. In Indonesia, women with breast cancer are diagnosed at a younger age, having premenopause, and at an advanced stage [4], [5].

The increasing incidence of breast cancer and better management has led to an increase in the prevalence of breast cancer patients [6]. In addition to surgery as the main therapy for breast cancer, other therapeutic modalities include chemotherapy, radiotherapy, hormonal therapy, and targeted therapy according to the characteristics of the patient and cancer [7], [8]. Chemotherapy has increased the survival of breast cancer [9], but the effects of chemotherapy on the reproductive system, especially chemotherapy-induced amenorrhea (CIA), can cause menopause, infertility, and psychological distress [10], [11]. CIA incidence can be permanent or reversible [11], [12]. Several factors have been reported to be associated with the incidence of permanent amenorrhea [13], [14], [15]. At present, there is no CIA research on breast cancer patients in Indonesia. This study aims to find out the factors related to menstruation return in the CIA of breast cancer chemotherapy at Dr. Moewardi General Hospital, Surakarta.

Materials and Methods

The population of this study was new breast cancer patients with premenopausal status when...
they started receiving chemotherapy at Dr. Moewardi Hospital, Surakarta, Indonesia, from January 2019 to July 2021. This retrospective study was conducted with the approval of the Ethics Committee of Dr. Moewardi General Hospital, Surakarta. The criteria for the subjects of this study were Stage I–IV breast cancer patients, having premenopause, no history of chemotherapy, no history of oophorectomy/hysterectomy therapy, no history of radiation therapy to the pelvis, and not receiving gonadotropin-releasing hormone analogs.

All patients who met the criteria and gave informed consent to participate were included in this study. Demographic data, breast cancer characteristics, and details of anti-cancer treatment were reviewed and recorded from medical records. Menstrual status was obtained from the patient’s anamnesis; the patient was declared premenopausal if, during the diagnosis, they still had regular menstruation in the past 3 months and did not receive hormone replacement therapy. The patient was declared to have CIA if they experienced a period of amenorrhea for more than or equal to 3 months after receiving chemotherapy; CIA was declared persistent if, in the 12-month follow-up period after the completion of chemotherapy, there was no return of menstruation [16].

The research variables include age, education, marital status, occupation, stage, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2), body mass index (BMI) as classified by the Ministry of Health of Indonesia, parity, and menarche. Research variables in the form of categorical data are presented in the distribution of frequency and percentage values. To determine the relationship, the Chi-square/Fisher’s exact test was performed. Risk factor analysis on the incidence of permanent CIA in this study was carried out using a bivariate logistic regression test then followed by multivariate analysis on variables that had p < 0.2 in bivariate analysis. All data were processed and analyzed using SPSS 22.

Results

In this study, 105 premenopausal breast cancer patients who received chemotherapy were found. Of these patients, 97 (93.38%) patients experienced chemotherapy-induced amenorrhea and 8 patients (6.62%) continued to menstruate. Of all the subjects having CIA, 49 patients (46.67%) menstruated again after the completion of chemotherapy, there was no return of menstruation [16].

A total of 44 breast cancer patients (45.5%) who had CIA were <45 years old, and 53 patients (54.6%) were >45 years old; most of the education was elementary school by 34 patients (35.1%); most of the patients (92 patients or 94.8%) were married; based on the occupation, most of the patients worked, that is, 59 patients (60.8%) with mostly Stage-III cancer, namely, 56 patients (57.7%). Based on the CPI, 28 patients (28.9%) had positive ER, 38 patients (39.2%) had positive PR, and 12 patients (12.4%) had positive Her-2. The BMI of most patients (57 patients or 58.8%) was in the normal category. For parity, most of them (92 patients or 94.8%) had given birth. The age at menarche was mostly >12 years (93 patients or 95.9%). For more details, refer to Table 1.

Table 1 shows that age has a significant relationship with the incidence of permanent CIA (p =< 0.001), where patients aged >45 years tend to have permanent CIA incidence with a proportion of 42 patients (87.5%) (p < 0.05). Meanwhile, education level (p = 0.240), marital status (p = 362), occupation (p=0.184), staging (p=0.294), PR (p = 0.184), Her 2 (p = 0.203), BMI (p = 0.276), parity (p = 0.362), and menarche (p = 0.362) did not show a significant relationship with the incidence of amenorrhea (p > 0.05).

Risk factor analysis on the incidence of permanent CIA in this study was carried out using a bivariate logistic regression test followed by multivariate analysis on variables that had p < 0.2 in bivariate analysis. The OR value is used to determine the level of risk for permanent CIA incidence and significant if p < 0.05. The analysis of risk factors for the incidence of permanent CIA is shown in Table 2 as follows.

The multivariate analysis showed that age >45 years (OR = 75.117; 95% CI = 12.671–445.311; p < 0.001) was a significant factor in the incidence of permanent CIA. It was significant if p = 0.05. ER: Estrogen receptor, PR: Progesterone receptor, Her-2: Human epidermal growth factor receptor 2, BMI: Body mass index.
p = < 0.001) was the most dominant risk factor associated with the incidence of permanent CIA, while other variables as risk factors for permanent CIA based on multivariate analysis were Stage III (R = 6.677; 95% CI = 1.370–32.545; p = 0.019) compared to Stages I and II, and BMI in the normal category (OR = 5.485; 95% CI = 1.083–27.786; p = 0.040) compared to excess BMI. Demographic factors such as education, occupation, and marital status did not show a relationship with permanent CIA. Likewise, ER, PR, Her-2, parity, and menarche were not found to be associated with the incidence of permanent CIA.

**Discussion**

In this study, the CIA incidence of breast cancer patients was found in 97 patients (92.38%); 8 patients (7.62%) continued to menstruate regularly or did not experience CIA. Of all the subjects having CIA, 49 CIA patients (46.67%) experienced reversible CIA while the other 48 (45.71%) had persistent CIA. The incidence of amenorrhea in premenopausal patients receiving breast cancer chemotherapy is common. Various reports show the CIA incidence varies from 10% to 93% [12], [17]; the incidence of CIA in our study is similar to the report of Koga et al.; the incidence of CIA in Japanese women is 96% [18]. The study by Jeon et al. reported the incidence of CIA in Korean women as 88% [10] while the Supraset al. study reported the incidence of CIA in Thai women by 92.2% [14]. The high CIA incident range is due to differences in CIA definitions, length of follow-up, and patient characteristics in each study [17]. In many studies, the factor most associated with the incidence of CIA is age [10], [11], [17], [18]. However, the study by Pourali et al. reported no relationship between age and the incidence of CIA [19].

Based on age group, the incidence of CIA at the age group of 45 years occurred in 44 patients (45.4%) and the age group of >45 years occurred in 53 patients (64.6%), where the incidence of menstruation return in the age group of 45 years was in 38 patients (77.6%), and only 11 patients (22.4%) got menstruation return in the age group of >45 years. In multivariate analysis, age over 45 years was associated with permanent CIA. Pérez-Fidalgo et al. reported that the incidence of CIA in the age group of >45 years reached 95%; the proportion of CIA decreased to 52% in the age group of <40 years [20]. The age limit of 45 years is also a significant factor in predicting the irreversible incidence of CIA [14]. Meng et al. reported that the age group of under 45 years rarely experiences post-CIA menopause and has a high probability of menstruation return; thus, age is a predictor factor for the incidence of reversible CIA and the occurrence of menopause. Likewise, Supraset al. and Koga et al. reported that older age increases the risk of permanent CIA [14], [18]. The decrease in the number and quality of oocytes in the ovarian cortex follicles is a physiological aging process of the reproductive system [21]. Additional chemotherapy has a toxic effect that makes the elderly more susceptible to permanent CIA.

In the multivariate analysis, the relationship between BMI and permanent CIA was found. Some studies have reported that BMI is associated with the CIA while others found no relationship. Likewise, Zaccarelli et al. reported that BMI was not associated with CIA in breast cancer patients receiving anthracycline and cyclophosphamide chemotherapy [22]. Abusief et al. reported in their study that BMI was not associated with permanent CIA [15], [19]. The study by Lee et al. demonstrated that higher BMI showed more recovery of ovarian function [23]. Another study by Jeon et al. reported that CIA was associated with age, instead of BMI and tamoxifen therapy [10]. In this study, higher

---

**Table 2: Bivariate and multivariate analysis of risk factors on permanent CIA incidence**

| Variable                  | Bivariate OR (95%CI) | p-value | Multivariate OR (95%CI) | p-value |
|---------------------------|----------------------|---------|------------------------|---------|
| Age                       |                      |         |                        |         |
| ≤45 years                 | Ref.                 | Ref.    | Ref.                   | Ref.    |
| >45 years                 | 24.182 (8.153–71.223) | <0.001  | 73.144 (12.626–423.680) | <0.001* |
| Education                 |                      |         |                        |         |
| Elementary school         | 0.893 (0.241–3.308)  | 0.857   | 0.334 (0.087–1.284)    | 0.110   |
| Junior high school        | 0.521 (0.129–2.107)  | 0.360   | 0.230 (0.026–2.005)    | 0.183   |
| Senior high school        | 0.347 (0.089–1.351)  | 0.127   | 0.183                  |         |
| University                |                      |         |                        |         |
| Married                   | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Yes                       | 0.239 (0.026–2.224)  | 0.362   | 0.086                  |         |
| No                        | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Occupation                |                      |         |                        |         |
| Not Working               | Ref.                 | 0.184   | 0.334 (0.087–1.284)    | 0.110   |
| Working                   | 0.673 (0.251–1.306)  | 0.573   | 0.334                  |         |
| Staging                   |                      |         |                        |         |
| Stages I and II           | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Stage III                 | 2.108 (0.822–6.408)  | 0.121   | 6.576                  | 0.019*  |
| Stage IV                  | 1.700 (0.460–2.860)  | 0.426   | 1.371–31.538           |         |
| ER                        |                      |         |                        |         |
| Negative                  | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Positive                  | 2.340 (0.944–5.801)  | 0.063   | 5.947                  | 0.086   |
| PR                        |                      |         |                        |         |
| Negative                  | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Positive                  | 1.745 (0.766–3.978)  | 0.184   | 2.886 (0.457–18.239)   | 0.280   |
| Her-2                     |                      |         |                        |         |
| Negative                  | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Positive                  | 2.250 (0.630–8.040)  | 0.203   | 0.041                 |         |
| BMI                       |                      |         |                        |         |
| Underweight (<18.4)       | 0.714 (0.115–4.451)  | 0.719   | 0.189                  | 0.093   |
| Normal (18.5–25)          | 1.829 (0.774–4.323)  | 0.169   | 5.093 (1.072–24.197)   | 0.041*  |
| Overweight (>25)          | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Parity                    |                      |         |                        |         |
| Nullipara                 | Ref.                 | Ref.    | Ref.                   | Ref.    |
| Multiparity               | 4.178 (0.450–38.818) | 0.362   | 0.362                  |         |
| Menarche                  |                      |         |                        |         |
| ≤12 years                 | Ref.                 | Ref.    | Ref.                   | Ref.    |
| >12 years                 | 0.313 (0.031–3.115)  | 0.362   | 0.041                 |         |

ER: Estrogen receptor, PR: Progesterone receptor, Her-2: Human epidermal growth factor receptor 2, BMI: Body mass index.
BMI was more protective against CIA permanent incidence. This may be related to the cutoff value of BMI for Indonesians based on the classification of the Ministry of Health of Indonesia. In addition, there are differences in the relationship between BMI, percentage, and distribution of fat in the population due to different CIA effects. Changes in the pharmacokinetics of chemotherapy drugs in patients with higher BMI may lead to reduced gonadal toxic effects. Another possibility is the tendency of giving lower chemotherapy doses in patients with high BMI due to concerns about the side effects of chemotherapy.

There was also an association between permanent CIA incidence and disease stage. Pourali et al. found no association of amenorrhea with stage, hormone receptor status, and BMI [19]. The previous study by Di Cosimo et al. also found no significant association between CIA and tumor size, involvement of axillary nodes, stage of disease, and receptor status [24]. The relationship between persistent CIA at an advanced stage may be related to the number of regimens and the duration of chemotherapy given.

In this study, the chemotherapy regimen and tamoxifen therapy with the incidence of permanent CIA were not analyzed. Pérez-Fidalgo JA et al. reported no significant association between CIA chemotherapy regimens [20]. The study by Suprasert et al. stated that tamoxifen therapy was not associated with persistent CIA [14]. A meta-analysis study also stated that there was no significant relationship between tamoxifen and the incidence of persistent CIA [17]. This is in contrast to Meng et al. reporting an association between CIA and tamoxifen therapy [4]. The mechanism of cytotoxic agents causing CIA was described by Luo et al. through experiments in experimental animals (C57BL/6 mice) which found the role of inflammation regulation, SDF-1/CXCR4, and cellular apoptosis in the ovarian tissue that played a role in premature ovarian failure [25]. However, Yarso et al. found that chemotherapy abolished the effects of SDF1α/CXCR4 in breast cancer patients [26]. This indicates that other factors play a role in the mechanism of ovarian damage due to chemotherapy through complex interactions.

With the limit of CIA for 12 months, we assessed as permanent CIA, CIA reversible was found in 46.67% of patients from 93.38% who experienced CIA. Sukumvanich et al. reported that 41% of BC survivors had amenorrhea during therapy, but menstruation returned within 3 years of chemotherapy in 48% of patients [13]. On the other hand, Jeon et al. in their study revealed that within 5 years, the rate of menstruation return was found in 48.6% of patients [10]. This finding suggests that prolonged periods of amenorrhea may decrease the patient’s chances of getting menses again.

### Conclusion

This study showed that the incidence of CIA in premenopausal breast cancer patients reached 93.38%; 45.71% of patients had persistent CIA, and age was the main factor associated with this incident. Other factors related to this study are staging and BMI.

### References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. https://doi.org/10.3322/caac.21660
PMid:35353838

2. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43-6. https://doi.org/10.7314/apjcp.2016.17.e3.43
PMid:27165206

3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. https://doi.org/10.1002/ijc.29210
PMid:25220842

4. Manuaba IB., Wijaya IG. The relationship between immunohistochemical subtypes and age in breast cancer patients at Sanglah General Hospital, Denpasar. E-J Med Udayana. 2017;6(3):1-5. https://doi.org/10.36565/jab.v9i2.210

5. Trieu PD, Mello-Thoms C, Brennan PC. Female breast cancer in Vietnam: A comparison across Asian specific regions. Cancer Biol Med. 2015;12(3):238-45.
PMid:26487968

6. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505-27.
PMid:26181261

7. Moo T, Sanford R, Dang C, Morrow M, Sloan M, Cancer K, et al. Overview of Breast Cancer Therapy. HHS Public Access. 2019;13(3):339-54.

8. Tyagi NK, Dhesy-Thind S. Clinical practice guidelines in breast cancer.Curr Oncol. 2018;25 Suppl 1:S151-60.
PMid:29910668

9. Rossi L, Stevens D, Pierga JY, Lerebours F, Reyal F, Robain M, et al. Impact of adjuvant chemotherapy on breast cancer survival: A real-world population. PLoS One. 2015;10(7):e0132853.
PMid:26214853

10. Jeon SJ, Lee Ji, Jeon MJ, Lee M. Prognostic effects of adjuvant chemotherapy-induced amenorrhea and subsequent resumption of menstruation for premenopausal breast cancer patients. Medicine (Baltimore). 2016;95(14):e3301. https://doi.org/10.1097/md.0000000000003301
PMid:27057900

11. Meng K, Tian W, Zhou M, Chen H, Deng Y. Impact of chemotherapy-induced amenorrhea in breast cancer patients:
The evaluation of ovarian function by menstrual history and hormonal levels. World J Surg Oncol. 2013;11:101. https://doi.org/10.1186/1477-7819-11-101
PMid:23688389

12. Torino F, Barnabei A, de Vecchis L, Sini V, Schittulli F, Marchetti P, et al. Chemotherapy-induced ovarian toxicity in patients affected by endocrine-responsive early breast cancer. Crit Rev Oncol Hematol. 2014;89(1):27-42. https://doi.org/10.1016/j.critrevonc.2013.07.007
PMid:23953684

13. Sukumvanich P, Case LD, van Zee K, Singletary SE, Paskett ED, Petrek JA, et al. Incidence and time course of bleeding after long-term amenorrhea after breast cancer treatment: A prospective study. Cancer. 2010;116(13):3102-11. https://doi.org/10.1002/cncr.25106
PMid:20564648

14. Suprasert P, Khunthong P, Somwangprasert A. Prevalence and potential factors related to irreversible chemotherapy-induced amenorrhea in premenopausal breast cancer patients. Asian Pac J Cancer Care. 2020;5(3):167-72. https://doi.org/10.31557/apjcc.2020.5.3.167-172

15. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. Relationship between reproductive history, anthropometrics, lifestyle factors, and the likelihood of persistent chemotherapy-related amenorrhea in women with premenopausal breast cancer. Fertil Steril. 2012;97(1):154-9. https://doi.org/10.1016/j.fertnstert.2011.10.005
PMid:22192139

16. Okanami Y, Ito Y, Watanabe C. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane. Breast Cancer. 2011;18(3):182-8. https://doi.org/10.1007/s12282-011-0256-7
PMid:21394515

17. Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: A systematic review and meta-analysis. Acta Oncol. 2016;55(6):664-70. https://doi.org/10.3109/02841075.2016.1155738
PMid:27105082

18. Koga C, Akiyoshi S, Ishida M, Nakamura Y, Ohno S, Tokunaga E. Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer. 2017;24(5):714-9. https://doi.org/10.1007/s12282-017-0764-1
PMid:28243923

19. Pourali L, Taghizadeh AK, Ghavamnasiri MR, Khoshroo F, Hosseini S, Asadi M, et al. Incidence of chemotherapy-induced amenorrhea after adjuvant chemotherapy with taxane and anthracyclines in young patients with breast cancer. Iran J Cancer Prev. 2013;6(3):147-50. https://doi.org/10.1016/s0960-9776(13)30106-7
PMid:25250125

20. Pérez-Fidalgo JA, Roselló E, García-Garré E, Jorá E, Martin-Martorell P, Bermejo B, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: The impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat. 2010;120(1):245-51. https://doi.org/10.1007/s10549-009-0426-x
PMid:19575291

21. Şükür YE, Kvançlı IB, Özmen B. Ovarian aging and premature ovarian failure. J Turk Ger Gynecol Assoc. 2014;15(3):190-6. https://doi.org/10.5152/jtggsa.2014.0022
PMid:25317048

22. Zaccarelli E, Rossi L, Tomao F, Giordani E, Vernico M, Strudel M, et al. Body mass index (BMI) and amenorrhea in premenopausal breast cancer patients (PBC) treated with adjuvant docetaxel and cyclophosphamide chemotherapy (CT). Int J Gynecol Cancer. 2014;24:18-9. Available from: https://www.researchgate.net/publication/269407279_BODY_MASS_INDEX_BMI_AND_AMENORRHEA_IN_PREMENOPAUSAL_BREAST_CANCER_PATIENTS_PBC_TREATED_WITH_ADJUVANT_ANTRACYCLINE_AND_CYCLOPHOSPHAMIDE_CHEMOTHERAPY_CT. [Last accessed on 2021 Jun 21].
https://doi.org/10.1200/jco.2014.32.15_suppl.e12000

23. Lee JH, Shin DS, Kim HA, Kim YH, Paik NS, Moon NM, et al. Recovery of ovarian function with aromatase inhibitors: In young breast cancer patients (<45) with chemotherapy-induced amenorrhea. J Breast Cancer. 2008;11(3):133-8. https://doi.org/10.4048/jbc.2008.11.3.133

24. di Cosimo S, Alimonti A, Ferretti G, Sperduti I, Carlini P, Papaldo P, et al. Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann Oncol. 2004;15(7):1065-71. https://doi.org/10.1093/annonc/mdh266
PMid:15205200

25. Luo Q, Yin N, Zhang L, Yuan W, Zhao W, Luan X, et al. Role of SDF-1/CXCR4 and cytokines in the development of ovary injury in chemotherapy drug induced premature ovarian failure mice. Life Sci. 2017;179:103-9. https://doi.org/10.1016/j.lfs.2017.05.001
PMid:28478265

26. Yarso KY, Bellynda M, Azmiardi A, Wasita B, Heriyanto DS, Astuti I, et al. Chemotherapy negates the effect of SDF1 mRNA to distant metastasis and poor overall survival in breast cancer patients. Asian Pac J Cancer Prev. 2021;22(3):757-66. https://doi.org/10.31557/apjcp.2021.22.3.757
PMid:33773539